Skip to main content
SpringerLink
Log in

Gestational Trophoblastic Disease

  • Chapter
  • First Online:
Gynecologic Oncology

  • 2350 Accesses

Abstract

Gestational trophoblastic disease (GTD) is a term that encompasses a spectrum of disorders all arising from the placenta, and specifically, from the villous trophoblast of the placenta. These diseases include hydatidiform mole (both complete and partial), invasive mole, choriocarcinoma (CCA), and placental site trophoblastic tumor (PSTT). The term gestational trophoblastic neoplasia (GTN) includes the disorders of invasive mole, CCA, and PSTT, as they have significant clinical impact. While in the past, this spectrum of diseases was known to have serious morbidity and mortality, with current diagnosis and treatment, cure rates are quoted to upwards of 98 % (Sebire and Seckle, BMJ 227:A1193, 2008). In this chapter, diagnosis, staging, and management of gestational trophoblastic disease are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sebire NJ, Seckle MJ. Gestational trophoblastic disease: current management of hydatidiform mole. BMJ. 2008;227:A1193.

    Article  Google Scholar 

  2. Palmer JR. Advances in the epidemiology of gestational trophoblastic disease. J Repro Med. 1994;39(3):155–62.

    CAS  Google Scholar 

  3. Smith HO. Gestational trophoblastic disease epidemiology and trends. Clin Obstet Gynecol. 2003;46(3):541–56.

    Article  PubMed  Google Scholar 

  4. Singh DK. Gestational trophoblastic disease. In: Karlan BY, Brostow RE, Li AJ, editors. Gynecologic oncology: clinical practice and surgical atlas. 1st ed. New York, NY: Mc Graw Hill; 2012. p. 157–71.

    Google Scholar 

  5. Parazzini F, La Vecchia C, Mangili G, et al. Dietary factors and risk of trophoblastic disease. Am J Obstet Gynecol. 1988;158(1):93–9.

    Article  CAS  PubMed  Google Scholar 

  6. Berkowitz RS, Im SS, Bernstein MR, et al. Gestational trophoblastic disease: subsequent pregnancy outcome, including repeat molar pregnancy. J Reprod Med. 1998;43:81–6.

    CAS  PubMed  Google Scholar 

  7. Bentley RC. Pathology of gestational trophoblastic disease. Clin Obstet Gynecol. 2003;46(3):513–22.

    Article  PubMed  Google Scholar 

  8. Soper JT, Lewis JL, Hammond CB. Gestational trophoblastic disease. In: Hoskins WJ, Perez CA, Young RC, editors. Principals and practice of gynecologic oncology. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1997. p. 1039–77.

    Google Scholar 

  9. Tang X, Yang F, Jia L, et al. Placental site trophoblastic tumor in the pelvic wall: a case report and review of literature. Indian J Pathol Microbiol. 2013;56(3):300–2.

    Article  PubMed  Google Scholar 

  10. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Singh M, Kindelberger D, Nagymanyoki Z, et al. Matrix metalloproteinases and their inhibitors and inducers in gestational trophoblastic disease and normal placenta. Gynecol Oncol. 2011;122:178–82.

    Article  CAS  PubMed  Google Scholar 

  12. Butler GS, Dean RA, Tam EM, et al. Pharmacoproteiomics of metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding. Mol Cell Biol. 2008;28:4896–914.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Szulman AE, Surti U. The syndromes of hydatidiform mole I and II. Am J Obstet Gynecol. 1978;132(1):20–7.

    CAS  PubMed  Google Scholar 

  14. Fukanaga M. Immunohistochemical characterization of p57 (KIP2) expression in early hydatidiform moles. Hum Pathol. 2002;33(12):1188–92.

    Article  Google Scholar 

  15. Hoffner L, Surti U. The genetics of gestational trophoblastic disease: a rare complication of pregnancy. Cancer Genet. 2012;205(3):63–77.

    Article  CAS  PubMed  Google Scholar 

  16. Fisher RA, Hodges MD, Newlands ES. Familial recurrent hydatidiform mole: a review. J Reprod Med. 2004;49(8):595–601.

    PubMed  Google Scholar 

  17. Kou YC, Shao L, Peng HH, et al. A recurrent intragenic genomic duplication, other novel mutations in NLRP7 and imprinting defects in recurrent biparental hydatidiform moles. Mol Hum Reprod. 2008;14(1):33–40.

    Article  CAS  PubMed  Google Scholar 

  18. Moglabey YB, Kircheisen R, Seoud M, et al. Genetic mapping of a maternal locus responsible for familial hydatidiform moles. Hum Mol Genet. 1999;8(4):667–71.

    Article  CAS  PubMed  Google Scholar 

  19. Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010;203(6):531–9.

    Article  PubMed  Google Scholar 

  20. Berkowitz RS, Goldstein DB, Bernstein MR. Natural history of partial molar pregnancy. Obstet Gynecol. 1985;66(5):677–81.

    CAS  PubMed  Google Scholar 

  21. Benson CB, Genest DR, Bernstein MR, et al. Sonographic appearance of first trimester complete hydatidiform moles. Ultrasound Obstet Gynecol. 2000;16(2):188–91.

    Article  CAS  PubMed  Google Scholar 

  22. Reid MH, McGahan JP, Oi R. Sonographic evaluation of hydatidiform mole and its look-alikes. AM J Roentgenol. 1983;140(2):307–11.

    Article  CAS  Google Scholar 

  23. Committee on Practice Bulletins-Gynecology. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin 53. Diagnosis and treatment of gestational trophoblastic neoplasms. Obstet Gynecol 2004;103:1365–73.

    Google Scholar 

  24. Mitchell H, Seckl MJ. Discrepancies between commercially available immunoassays in the detection of tumour-derived hCG. Mol Cell Endocrinol. 2007;260–262:310–3.

    Article  PubMed  Google Scholar 

  25. Genest DR, Laborde O, Berkowitz RS, et al. A clinicopathologic study of 153 cases of complete hydatidiform mole (1980–1990): histologic grade lacks prognostic significance. Obstet Gynecol. 1991;78:402–9.

    CAS  PubMed  Google Scholar 

  26. Kohorn EL. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. Int J Gynecol Cancer. 2001;11(1):73–7.

    Article  CAS  PubMed  Google Scholar 

  27. Cole L, Shahabi S, Butler S, et al. Utility of commonly used commercial human chorionic gonadotropin immunoassays in the diagnosis and management of trophoblastic diseases. Clin Chem. 2001;47(2):308–15.

    CAS  PubMed  Google Scholar 

  28. Garner EI, Feltmate CM, Goldstein DP, et al. The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. Gynecol Oncol. 2005;99(1):3–5.

    Article  PubMed  Google Scholar 

  29. Cole L, Khanlian SA, Giddings A, et al. Gestational trophoblastic diseases: 4. Presentation with persistent low positive human chorionic gonadotropin test results. Gynecol Oncol. 2006;102:165–72.

    Article  CAS  PubMed  Google Scholar 

  30. Palmieri C, Dhillon T, Fisher RA, et al. Management and outcome of healthy women with a persistently elevated beta-hCG. Gynecol Oncol. 2007;106(1):35–43.

    Article  PubMed  Google Scholar 

  31. Rotmensch S, Cole LA. False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations. Lancet. 2000;355(9205):712–5.

    Article  CAS  PubMed  Google Scholar 

  32. Cole L, Khanian S. Inappropriate management of women with persistent low hCG results. J Reprod Med. 2004;49(6):423–32.

    PubMed  Google Scholar 

  33. El G, Garrett A, Goldstein DP, et al. Significance of chest computed tomography findings in the evaluation and treatemtn of persistent gestational trophoblastic neoplasia. J Reprod Med. 2004;49(6):411–4.

    Google Scholar 

  34. Berry E, Hagopian GS, Lurain JR. Vaginal metastases in gestational trophoblastic neoplasia. J Reprod Med. 2006;53(7):487–92.

    Google Scholar 

  35. Ngan HY, Bender H, Benedet JL, et al. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet. 2003;83 suppl 1:175–7.

    Article  PubMed  Google Scholar 

  36. Ngan HY, Kohorn EI, Cole LA, et al. Trophoblastic disease. Int J Gynaecol Obstet. 2012;119S2:S130–6.

    Article  Google Scholar 

  37. Berkowitz RS, Goldstein DP. Molar pregnancy. N Engl J Med. 2009;360:1639–45.

    Article  CAS  PubMed  Google Scholar 

  38. Hancock BW, Tidy JA. Current management of molar pregnancy. J Reprod Med. 2002;47(5):347–54.

    PubMed  Google Scholar 

  39. Tidy JA, Gillespie AM, Bright N, et al. Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecol Oncol. 2000;78(3 pt 1):309–12.

    Article  CAS  PubMed  Google Scholar 

  40. Limpongsanurak S. Prophylactic actinomycin D for high risk complete hydatidiform mole. J Reprod Med. 2001;46(2):110–6.

    CAS  PubMed  Google Scholar 

  41. Steller MA, Genest DR, Bernstein MR, et al. Natural history of twin pregnancy with complete hydatidiform mole and coexisting fetus. Obstet Gynecol. 1994;83:35–42.

    CAS  PubMed  Google Scholar 

  42. Alazzam M, Tidy J, Hancock BW, et al. First line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2009;(1):CD007102.

    Google Scholar 

  43. Turan T, Karacay O, Tulunay G, et al. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2006;16(3):1432–8.

    Article  CAS  PubMed  Google Scholar 

  44. Feng F, Xiang Y. Surgical management of chemotherapy-resistant gestational trophoblastic neoplasia. Expert Rev Anticancer Ther. 2010;10(1):71–80.

    Article  PubMed  Google Scholar 

  45. Powles T, Savage PM, Stebbing J, et al. A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer. 2007;96(5):732–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Wang J, Short D, Sebire NJ, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Ann Oncol. 2008;19(9):1578–83.

    Article  CAS  PubMed  Google Scholar 

  47. Alifrangis C, Agarwal R, Short D, et al. EMA/CO for high risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol. 2013;31(2):280–6.

    Article  CAS  PubMed  Google Scholar 

  48. Hassadia A, Gillespie A, Tidy J, et al. Placental site trophoblastic tumour: clinical features and management. Gynecol Oncol. 2005;99(3):603–7.

    Article  PubMed  Google Scholar 

  49. Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 2011;204(1):11–8.

    Article  PubMed  Google Scholar 

  50. Curry SL, Twiggs L, Slayton R, et al. Preliminary report of toxicity in a randomized comparison of methotrexate, actinomycin D, and chlorambucil (MAC) vs modified bagshawe regimen in “poor prognosis4” gestational trophoblastic disease. Obstet Gynecol. 1989;73(3):357–62.

    CAS  PubMed  Google Scholar 

  51. Petrilli ES, Twiggs LB, Blessing JA, et al. Single dose actinomycin-D treatment for nonmetastatic gestational trophoblastic disease: a prospective phase II trial of the Gynecologic Oncology Group. Cancer. 1987;60:2173–6.

    Article  CAS  PubMed  Google Scholar 

  52. Homesley HD, Blessing JA, Rettenmaier M, et al. Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease (A Gynecologic Oncology Group Study). Obstet Gynecol. 1988;72(3-I):413–8.

    CAS  PubMed  Google Scholar 

  53. Sutton GP, Soper JT, Blessing JA, et al. Ifosfamide alone and in combination in the treatment of refractory malignant gestational trophoblastic disease. Am J Obstet Gynecol. 1992;167(2):489–95.

    Article  CAS  PubMed  Google Scholar 

  54. Osborne RJ, Filiaci V, Schink JC, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol. 2011;19(7):825–31.

    Article  Google Scholar 

  55. Lertkhachonsuk AA, Isranqura N, Wilailak S, et al. Actinomycin d vs. methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial. Int J Gynecol Cancer. 2009;19(5):985–8.

    Article  PubMed  Google Scholar 

  56. Abrao RA, de Andrade JM, Tiezzi DG, et al. Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens. Gynecol Oncol. 2008;108(1):149–53.

    Article  CAS  PubMed  Google Scholar 

  57. Escobar PF, Lurain JR, Singh DK, et al. Treratment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecol Oncol. 2003;91(3):552–7.

    Article  CAS  PubMed  Google Scholar 

  58. Lybol C, Thomas CM, Blanken EA, et al. Ccomparin cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. Eur J Cancer. 2013;49(4):860–7.

    Article  CAS  PubMed  Google Scholar 

  59. Reynolds, RK. Overview of gynecologic oncology. University of Michigan Gynecologic Oncology handbook. 11th ed. Ann Arbor; 2010. pp 24–8.

    Google Scholar 

  60. Growden WB, Wolfberg AJ, Goldstein DP, et al. Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia. Gynecol Oncol. 2009;112:353–7.

    Article  Google Scholar 

  61. Berkowitz RS, Goldstein DP. Current advances in the management of gestational trophoblastic disease. Gynecol Oncol. 2013;128(1):3–5.

    Article  PubMed  Google Scholar 

  62. Shah NT, Barroilhet L, Berkowitz RS, et al. A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia. J Reprod Med. 2012;57(5–6):211–8.

    PubMed  Google Scholar 

  63. Lybol C, Sweep FC, Harvey R, et al. Relapse rates after two vs. three consolidation coursres of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2012;125:576–9.

    Article  CAS  PubMed  Google Scholar 

  64. Ghaemmaghami F, Behtash N, Soleimani K, et al. Management of patients with metastatic gestational trophoblastic tumor. Gynecol Oncol. 2004;94(1):1870190.

    Google Scholar 

  65. Newlands ES, Holden L, Seckl MJ, et al. Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med. 2002;47(6):465–71.

    CAS  PubMed  Google Scholar 

  66. Tomoda Y, Arii Y, Kaseki S, et al. Surgical indications for resection in pulmonary metastasis of choriocarcinoma. Cancer. 1980;46(12):2723–30.

    Article  CAS  PubMed  Google Scholar 

  67. Grumbine FC, Rosenshein NB, Brereton HD, et al. Management of liver metastasis from gestational trophoblastic neoplasia. Am J Obstet Gynecol. 1980;137:959–96.

    CAS  PubMed  Google Scholar 

  68. Yang J, Xiang Y, Wan X, et al. The prognosis of gestational trophoblastic neoplasia patient with residual lung tumor after completing treatment. Gynecol Oncol. 2006;103(2):479–82.

    Article  PubMed  Google Scholar 

  69. Mao Y, Wan X, Lv W, et al. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen. Int J Gynaecol Obstet. 2007;98(1):44–7.

    Article  CAS  PubMed  Google Scholar 

  70. Lurain JR, Schink JC. Importance of salvage therapy in the management of high risk gestational trophoblastic neoplasia. J Reprod Med. 2012;57(5–6):219–24.

    PubMed  Google Scholar 

  71. Osborne R, Covens A, Mirchandani D, et al. Successful salvage of relapsed high-risk gestational trophoblastic neoplasia patients using a novel paclitaxel-containing doublet. J Reprod Med. 2004;49(8):655–61.

    CAS  PubMed  Google Scholar 

  72. Hoekstra AV, Lurain JR, Rademaker AW, et al. Gestational trophoblastic neoplasia: treatment outcomes. Obstet Gynecol. 2008;112(2 Pt 1):251–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women’s Health, University of Minnesota Medical Center, Fairview, 420 Delaware Street SE, MM395, Minneapolis, MN, 55455, USA

    Elizabeth L. Dickson M.D. & Sally A. Mullany M.D.

Authors
  1. Elizabeth L. Dickson M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sally A. Mullany M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth L. Dickson M.D. .

Editor information

Editors and Affiliations

  1. Dept. of Obstetrics and Gynecology Building 56, Suite 260, University of Calfornia, Irvine Irvine Medical Center, Orange, California, USA

    Ramez N. Eskander

  2. Dept. of Obstetrics and Gynecology Building 56, Room 260, University of California, Irvine Irvine Medical Center, Orange, California, USA

    Robert E. Bristow

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Dickson, E.L., Mullany, S.A. (2015). Gestational Trophoblastic Disease. In: Eskander, R., Bristow, R. (eds) Gynecologic Oncology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1976-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1976-5_5

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1975-8

  • Online ISBN: 978-1-4939-1976-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation